Topline Phase III pomalidomide data bolster Celgene's prospects in multiple myeloma
This article was originally published in Scrip
Executive Summary
Celgene reported positive topline data on 23 October from a Phase III clinical trial for pomalidomide that could position the oral immunomodulatory agent well in the underserved multiple myeloma market after detailed results from the study, known as MM-003, are reported at a future medical conference.